てんかんデバイス市場規模、シェア、成長分析：製品タイプ別、技術プラットフォーム別、エンドユーザー別、地域別 - 産業予測 2025～2032年

てんかんデバイス市場規模は2023年に22億米ドルと評価され、2024年の24億2,000万米ドルから2032年には51億9,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは10.0％で成長する見通しです。

てんかんデバイスの世界市場は、てんかんの有病率の上昇と医療技術の進歩に後押しされ、顕著な成長軌道に乗っています。てんかん発作の検出、管理、患者の転帰を改善することを目的とした植え込み型神経刺激装置やウェアラブル発作モニタリングツールなどのてんかんデバイスに対する需要が高まっています。しかし、市場の拡大は、高コスト、限られた償還オプション、訓練を受けた専門家の不足といったハードルに直面しています。現在、北米が市場をリードしているが、アジア太平洋地域は、ヘルスケアインフラの強化やてんかん管理に対する意識の高まりに後押しされ、力強い成長を遂げています。主な動向としては、継続的な技術革新や患者中心のソリューションへの注目が挙げられ、ヘルスケアプロバイダーと患者双方のニーズの進化を反映しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

てんかんデバイス市場規模：製品タイプ別& CAGR（2025-2032）

• 市場概要
• 従来のデバイス
• ウェアラブルデバイス
• 埋め込み型デバイス
• 食事療法

てんかんデバイス市場規模：技術プラットフォーム& CAGR（2025-2032）

• 市場概要
• 迷走神経刺激療法
• 脳深部刺激療法
• 加速度センサー
• 応答性神経刺激療法

てんかんデバイス市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院と診療所
• 神経学センター
• 在宅ケア

てんかんデバイス市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Medtronic plc（Ireland）
• LivaNova PLC（UK）
• Abbott Laboratories（USA）
• Boston Scientific Corporation（USA）
• Neuropace, Inc.（USA）
• Nihon Kohden Corporation（Japan）
• Natus Medical Incorporated（USA）
• Compumedics Limited（Australia）
• UCB S.A.（Belgium）
• Sunovion Pharmaceuticals Inc.（USA）
• SK Biopharmaceuticals（South Korea）
• Zogenix, Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Johnson & Johnson（USA）
• Masimo Corporation（USA）

結論と提言

Epilepsy Devices Market size was valued at USD 2.2 billion in 2023 and is poised to grow from USD 2.42 billion in 2024 to USD 5.19 billion by 2032, growing at a CAGR of 10.0% during the forecast period (2025-2032).

The Global Epilepsy Devices Market is on a notable growth trajectory, fueled by the rising prevalence of epilepsy and advancements in medical technology. There is a growing demand for epilepsy devices, including implantable neurostimulators and wearable seizure monitoring tools, which aim to improve seizure detection, management, and patient outcomes. However, market expansion faces hurdles such as high costs, limited reimbursement options, and a shortage of trained professionals. North America currently leads the market, while the Asia-Pacific region is experiencing robust growth, bolstered by enhancements in healthcare infrastructure and increased awareness of epilepsy management. Key trends include continuous technological innovation and a focus on patient-centric solutions, reflecting the evolving needs of both healthcare providers and patients.

Top-down and bottom-up approaches were used to estimate and validate the size of the Epilepsy Devices market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Epilepsy Devices Market Segments Analysis

Global Epilepsy Devices Market is segmented by Product Type, Technology Platform, End User and region. Based on Product Type, the market is segmented into Conventional Devices, Wearable Devices, Implantable Devices and Diet. Based on Technology Platform, the market is segmented into Vagus Nerve Stimulation, Deep Brain Stimulation, Accelerometery and Responsive Neurostimulation. Based on End User, the market is segmented into Hospitals and Clinics, Neurology Centers and Home Care Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Epilepsy Devices Market

The rising global incidence of epilepsy has significantly expanded the patient population, which in turn has heightened the demand for innovative medical solutions. Recent technological advancements in epilepsy devices, such as implantable neurostimulators and responsive neurostimulation systems, have greatly enhanced seizure control and positively impacted patient outcomes. Additionally, the increasing awareness surrounding epilepsy, coupled with the critical importance of early diagnosis and intervention, has further stimulated market growth. This confluence of factors not only showcases the urgent need for effective treatment options but also highlights the evolving landscape of the epilepsy devices market as it adapts to patients' needs.

Restraints in the Epilepsy Devices Market

A significant constraint within the epilepsy devices market is the high cost of advanced devices, which limits accessibility for a large segment of the population, particularly in regions with inadequate healthcare resources. Furthermore, reimbursement policies and insurance coverage limitations can hinder widespread adoption of these technologies. The requirement for specialized professionals to effectively implement and monitor these devices adds another layer of complexity, emphasizing the need for a robust healthcare infrastructure to support their use. Collectively, these factors contribute to the challenges faced in expanding the market reach of epilepsy devices, restricting their potential impact on patient care.

Market Trends of the Epilepsy Devices Market

The Epilepsy Devices market is witnessing a significant trend towards the adoption of wearable seizure monitoring devices, underscoring a shift towards patient-centric, non-invasive solutions that facilitate continuous monitoring. This growing emphasis on innovative technology is complemented by advancements in responsive neurostimulation, which offers real-time adaptive responses to abnormal brain activity. Moreover, the market is evolving towards personalized treatment approaches, with health care providers increasingly focusing on customizing therapeutic strategies to align with individual patient profiles. These factors highlight a holistic approach to epilepsy management, ultimately driving growth and enhancing the quality of life for those affected by the condition.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Epilepsy Devices Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Conventional Devices
• Wearable Devices
• Implantable Devices
• Diet

Global Epilepsy Devices Market Size by Technology Platform & CAGR (2025-2032)

• Market Overview
• Vagus Nerve Stimulation
• Deep Brain Stimulation
• Accelerometery
• Responsive Neurostimulation

Global Epilepsy Devices Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals and Clinics
• Neurology Centers
• Home Care Settings

Global Epilepsy Devices Market Size & CAGR (2025-2032)

• North America (Product Type, Technology Platform, End User)
  • US
  • Canada
• Europe (Product Type, Technology Platform, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Technology Platform, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Technology Platform, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Technology Platform, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LivaNova PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neuropace, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nihon Kohden Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natus Medical Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Compumedics Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sunovion Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SK Biopharmaceuticals (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zogenix, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Masimo Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations